11-Beta hydroxysteroid dehydrogenase type 1 inhibitors as anti-obesity/anti-diabetes compounds and 17-beta hydrosteroid dehydrogenase type I inhibitors as useful agents for the treatment of cancers, especially breast cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20050228038A1
SERIAL NO

11093493

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This invention is directed to the discovery that 11-Beta Hydroxysteroid Dehydrogenase Type 1 may be a common molecular etiology for visceral obesity and the metabolic syndrome of obesity as well a treatment for diabetes, especially type II diabetes. The present invention also relates to the use of certain compounds as inhibitors of 17-Beta Hydroxysteroid Dehydrogenase Type 1 and their use for the treatment of cancer, especially breast cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SCIENCE & TECHNOLOGY CORPORATION @ UNM801 UNIVERSITY BLVD SE SUITE 101 ALBUQUERQUE NM 87106

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Deck, Lorraine M Albuquerque, NM 14 131
Royer, Robert E Albuquerque, NM 10 93
Vander, Jagt David L Albuquerque, NM 18 182

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation